STAT

Opinion: The crusade for ‘religious liberty’ will reverberate badly in health care

Supreme Court nominee Judge Brett Kavanaugh looks over notes as he testifies before the Senate Judiciary Committee on the third day of his confirmation hearing on Capitol Hill.

Not that long ago, there was little difference between a physician and a preacher, a clinic and a chapel, a patient and a proselyte. Instead of prescribing medications, healers chanted hymns; instead of prescribing painkillers, they offered prayers.

Faith remains an integral part of human society and the modern hospital is a place where patients and physicians of all faiths work together. I am a Muslim physician who trained at a Boston hospital formed because none of the other local hospitals would offer Jewish doctors a job. On any given day, I see patients from myriad faiths, not to mention cultural backgrounds and sexual orientations.

I worry that the Trump administration is turning that directs federal agencies to give individuals and organizations great freedom to act — or refuse action — if they believe it impinges on their freedom of religious expression. This builds on the Department of Health and Human Services creating a , making it easier for doctors and nurses to refuse to treat patients based on religious or cultural objections.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
STAT1 min read
STAT+: Element Biosciences, An Illumina Rival, On Its Genomics Ambitions — And Why It Hasn’t Gone Public
Element Biosciences' modest growth comes at a time when some other players are struggling in a sequencer market dominated by Illumina.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

Related